Previous close | 2.4500 |
Open | 2.4500 |
Bid | 0.2000 |
Ask | 1.0500 |
Strike | 8.00 |
Expiry date | 2024-07-19 |
Day's range | 2.4500 - 2.4500 |
Contract range | N/A |
Volume | |
Open interest | 20 |
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.